Financials in USD. Standardized financial statements.
A compact view of how CASI Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $28.54M | $33.88M | $43.11M | $30.17M | $15.14M | $4.13M | $0 | $0 | $0 | $47,712 |
| Revenue Growth? | -15.8% | -21.4% | +42.9% | +99.2% | +266.5% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $17.39M | $13.83M | $15.83M | $12.56M | $9.51M | $3.94M | $1.67M | $117,779 | $66,451 | $6,274 |
| Gross Profit? | $11.15M | $20.05M | $27.28M | $17.61M | $5.63M | $196,000 | -$1.67M | -$117,779 | -$66,451 | $41,438 |
| Gross Margin? | +39.1% | +59.2% | +63.3% | +58.4% | +37.2% | +4.7% | 0.0% | 0.0% | 0.0% | +86.9% |
| Operating Expenses? | $50.77M | $45.13M | $53.77M | $59.13M | $58.41M | $40.19M | $26.50M | $10.75M | $9.42M | $7.19M |
| Operating Income? | -$39.62M | -$25.08M | -$26.49M | -$41.52M | -$52.78M | -$39.99M | -$26.50M | -$10.75M | $9.42M | $7.15M |
| EBITDA? | -$34.87M | -$21.54M | -$24.07M | -$33.40M | -$31.35M | -$37.43M | -$25.79M | -$10.64M | -$9.35M | -$7.06M |
| Income Before Tax | -$38.07M | -$26.29M | -$38.28M | -$35.84M | -$47.51M | -$45.36M | -$27.47M | -$10.77M | -$9.45M | -$7.21M |
| Income Tax Expense | $1.19M | -$81,000 | $1.98M | $0 | $0 | $0 | $0 | $14,976 | $33,808 | $82,455 |
| Net Income? | -$39.26M | -$26.94M | -$41.01M | -$36.65M | -$48.29M | -$45.36M | -$27.47M | -$10.77M | -$9.45M | -$7.21M |
| EPS? | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 | $-4.80 | $-3.24 | $-1.75 | $-1.69 | $-2.22 |
| Diluted EPS? | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 | $-4.80 | $-3.24 | $-1.75 | $-1.69 | $-2.22 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality